REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
24/11/2025
Voltar para busca
Dado oficial do USPTO
SIMCERE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
37
Atualização mais recente
25/11/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
02/09/2019
Data de registro
24/11/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/11/2020
Última transação
25/11/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
03
Localização do titular
CN
Examinador
VO, JULIE
Unidade examinadora
N50
Localização atual
TMO LAW OFFICE 123
Descrição da marca
The mark consists of a design of a running person composed of geometric figures, displayed within a flag-like rectangular design and the wording "SIMCERE" to the right.
Titulares e representantes
Titulares
Jiangsu Simcere Pharmaceutical Co., Ltd
Representantes
Dana Stewart-Mekdara Global Trademarks, Inc.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicated troches; Medicines for the prevention and treatment of cancercentral nervous system diseasesautoimmune diseasescardiovascular diseasesgastrointestinal diseaseslung diseaseosteoporosisricketschondropathyrenal osteopathyhypoparathyroidismdental diseaseshyperlipidemiadepressionhypercholesteremiakidney diseasesmusclo-skeletal disordersinfectionsbacterial infectionsall for human purposes; Biochemicial * Biochemical * drug for the prevention and treatment of cancercentral nervous system diseasesautoimmune diseasescardiovascular diseasesgastrointestinal diseaseslung diseaseosteoporosisricketschondropathyrenal osteopathyhypoparathyroidismdental diseaseshyperlipidemiadepressionhypercholesteremiakidney diseasesmusculo-skeletal disordersinfectionsbacterial infectionsall for human purposes; Chemical reagents for medical or veterinary purposes; Diagnostic preparations for medical purposes; Active pharmaceutical ingredientsextracts of hops for pharmaceutical purposeseucalyptus for pharmaceutical purposesmint for pharmaceutical purposesmalt for pharmaceutical purposespepsins for pharmaceutical purposesthymol for pharmaceutical purposesturpentine for pharmaceutical purposesflaxseed for pharmaceutical purposesferments for pharmaceutical purposescytostatics for pharmaceutical purposesbalms for pharmaceutical purposesdigestives for pharmaceutical purposesiodine for pharmaceutical purposesalcohol for pharmaceutical purposesstarch for pharmaceutical purposes; Pharmaceutical preparations for injection for the prevention and treatment of cancercentral nervous system diseasesautoimmune diseasescardiovascular diseasesgastrointestinal diseaseslung diseaseosteoporosisricketschondropathyrenal osteopathyhypoparathyroidismdental diseaseshyperlipidemiadepressionhypercholesteremiakidney diseasesmusclo-skeletal disordersinfectionsbacterial infectionsall for human purposes; Chinese patent medicines for the prevention and treatment of cancercentral nervous system diseasesautoimmune diseasescardiovascular diseasesgastrointestinal diseaseslung diseaseosteoporosisricketschondropathyrenal osteopathyhypoparathyroidismdental diseaseshyperlipidemiadepressionhypercholesteremiakidney diseasesandmusclo-skeletal disordersinfectionsbacterial infectionsall for human purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
37 publicações encontradas
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
18/04/2024
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
08/04/2024
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
12/09/2023
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
16/08/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/08/2023
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
08/08/2023
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
09/07/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
27/10/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
21/03/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
26/02/2021
FIMP
FINAL DISPOSITION PROCESSED
26/02/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/02/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
24/11/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/09/2020
PUBO
PUBLISHED FOR OPPOSITION
08/09/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/08/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/08/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
03/08/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/08/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
03/08/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/08/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
27/07/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
27/07/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
27/07/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/07/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/07/2020
RFNT
REFUSAL PROCESSED BY IB
13/03/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
22/02/2020
RFRR
REFUSAL PROCESSED BY MPU
22/02/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/01/2020
CNRT
NON-FINAL ACTION WRITTEN
27/01/2020
MAFR
APPLICATION FILING RECEIPT MAILED
21/01/2020
DOCK
ASSIGNED TO EXAMINER
17/01/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/01/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/01/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SIMCERE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.